Financing will fund launch readiness for SL1009 and support lifecycle expansion into Congenital Lactic Acidosis and additional pain indications for SL1002

融资将用于资助SL1009的上市准备，并支持SL1002在先天性乳酸酸中毒及其他疼痛适应症方面的生命周期扩展。

ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda

佐治亚州罗斯威尔，以及百慕大的都柏林和汉密尔顿

,

，

Sept. 15, 2026

2026年9月15日

/PRNewswire/ --

/美通社/ --

Saol Therapeutics

Saol 治疗公司

('Saol'), a privately held, clinical-stage pharmaceutical company, today announced a definitive agreement under which funds managed by Oaktree will provide up to $115 million in milestone-based capital, with an initial tranche funding near-term launch readiness and the remainder released as milestones are met..

私营临床阶段制药公司Saol今日宣布达成一项最终协议，根据该协议，由橡树资本管理的基金将提供高达1.15亿美元的基于里程碑的资本，其中首笔资金用于支持近期上市准备，其余资金将在达成相应里程碑后分批释放。

SL1009 (sodium dichloroacetate, DCA) is Saol's investigational candidate in development for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), a rare, life-threatening mitochondrial disease with no FDA-approved therapies. Saol

SL1009（二氯乙酸钠，DCA）是Saol公司正在开发的用于治疗丙酮酸脱氢酶复合体缺乏症（PDCD）的在研候选药物。PDCD是一种罕见的、危及生命的线粒体疾病，目前尚无美国食品药品监督管理局（FDA）批准的治疗方法。Saol

filed an NDA resubmission

提交了新药申请（NDA）的重新申报

on June 30, 2026, and the FDA has assigned a target action date of December 30, 2026. SL1009 is currently not approved by the FDA for any indication.

于2026年6月30日提交，美国食品药品监督管理局（FDA）已指定2026年12月30日为目标审评日期。SL1009目前未获FDA批准用于任何适应症。

Additional capital, released upon achievement of specified regulatory, clinical and commercial milestones, would support lifecycle opportunities for Saol's portfolio, including development of SL1009 for Congenital Lactic Acidosis (CLA) and expansion of SL1002 into additional pain indications and spasticity..

在达成特定的监管、临床和商业里程碑后释放的额外资本，将支持Saol产品组合的生命周期机会，包括开发用于先天性乳酸酸中毒（CLA）的SL1009，以及将SL1002拓展至更多的疼痛适应症和痉挛症治疗领域。

Separately, Saol announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) covering a method of administering SL1009 to patients following a ketogenic diet. The patent, once issued, is anticipated to expire in 2045.

此外，Saol 宣布已收到美国专利商标局（USPTO）发出的允许通知书，该通知涉及一种向遵循生酮饮食的患者施用 SL1009 的方法。该专利一旦授予，预计将于 2045 年到期。

'This financing gives Saol the capital to prepare a commercial organization for the launch of SL1009 while funding the next phase of our pipeline. We chose Oaktree because they understood the long-term opportunity across our portfolio, not just the near-term launch,' said Dave Penake, chief executive officer of Saol Therapeutics..

“这笔融资为Saol提供了资金，用于组建商业化团队以准备SL1009的上市，同时资助我们产品管线的下一阶段。我们选择Oaktree是因为他们理解我们整个产品组合的长期机遇，而不仅仅是近期的上市。”Saol Therapeutics首席执行官Dave Penake表示。

'We are excited to partner with Saol at this key stage in the company's evolution and believe that SL1009 has the potential to become a life-saving treatment for patients suffering from rare mitochondrial diseases,' said Kent Bailey, Managing Director, Life Sciences Lending at Oaktree. 'This new credit facility reflects Oaktree's confidence in Saol's experienced management team, and we look forward to supporting the company in their upcoming commercial and pipeline development activities.'.

“我们很高兴在公司发展的这一关键阶段与Saol合作，并相信SL1009有潜力成为挽救患有罕见线粒体疾病患者生命的治疗方案。”橡树资本生命科学贷款部门董事总经理Kent Bailey表示。“这项新的信贷安排体现了橡树资本对Saol经验丰富的管理团队的信心，我们期待支持该公司即将开展的商业化及管线开发活动。”

The transaction closed on September 11, 2026.

该交易于2026年9月11日完成。

About SL1009, Sodium Dichloroacetate (DCA)

关于SL1009，二氯乙酸钠（DCA）

SL1009 is an investigational product that, if approved, would be used with a proprietary dose-determining genetic test to treat an orphan pediatric-onset mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD). PDCD is a rare and life-threatening genetic disorder that can cause chronic energy deficit leading to lactic acidosis, profound developmental problems, and early childhood death.

SL1009 是一种在研产品，若获批准，将与专有的剂量确定基因检测联合使用，用于治疗一种孤儿型儿童期起病的线粒体疾病——丙酮酸脱氢酶复合体缺乏症（PDCD）。PDCD 是一种罕见且危及生命的遗传性疾病，可导致慢性能量不足，进而引发乳酸酸中毒、严重的发育问题以及幼儿期死亡。

There are currently no FDA-approved therapies for PDCD..

目前尚无FDA批准的PDCD疗法。

SL1009 has received Priority Review, Orphan Drug Designation, and Rare Pediatric Disease Designation, and Saol anticipates receiving a Priority Review Voucher (PRV) under the Rare Pediatric Disease Statute upon approval.  Saol and Medosome Biotec will be filing a 510(k) for the dose-determining genetic test, which would serve as a required companion diagnostic for patients prescribed SL1009..

SL1009已获得优先审评、孤儿药认定和罕见儿科疾病认定，Saol预计在该药物获批后，将根据《罕见儿科疾病法案》获得一张优先审评券（PRV）。Saol与Medosome Biotec将为用于确定剂量的基因检测提交510(k)申请，该检测将作为处方SL1009患者所需的伴随诊断。

About SL1002

关于SL1002

SL1002 is an investigational, novel perineural chemoneurolytic injection that utilizes Saol's proprietary CYCLOPHLEX™ technology.  It is currently being advanced in development for the treatment of chronic knee pain related to osteoarthritis and for limb spasticity, both in the adult population (18+)..

SL1002 是一种在研的新型经神经周围化学神经松解注射剂，采用 Saol 公司专有的 CYCLOPHLEX™ 技术。目前，该药正在推进开发，用于治疗成人（18 岁及以上）与骨关节炎相关的慢性膝痛以及肢体痉挛。

About Saol Therapeutics

关于 Saol Therapeutics

Saol Therapeutics (pronounced 'Sail') is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, Ga., Dublin, Ireland, and Hamilton, Bermuda. Saol is focused on development activity in CNS disorders such as spasticity and pain management, and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations.

Saol Therapeutics（发音为“Sail”）是一家私营的临床阶段制药公司，在佐治亚州罗斯韦尔、爱尔兰都柏林和百慕大汉密尔顿设有运营机构。Saol 专注于中枢神经系统疾病（如痉挛状态和疼痛管理）以及罕见病的开发活动。Saol 致力于为患者及治疗这些患者群体的医生提供并推进治疗方案。

For more information, visit .

更多信息，请访问。

www.saolrx.com

www.saolrx.com

.

。

About Oaktree

关于橡树资本

As a part of Brookfield's $416 billion credit platform, Oaktree is a premier global credit manager emphasizing an opportunistic, value-oriented, and risk-controlled approach to investing across credit, equity, and real estate.  To learn more about our global business and investment ethos, please visit Oaktree's website at .

作为布鲁克菲尔德4,160亿美元信贷平台的一部分，橡树资本是一家领先的全球信贷管理机构，强调在信贷、股权和房地产领域采取机会主义、价值导向且风险可控的投资方法。如需了解更多关于我们全球业务和投资理念的信息，请访问橡树资本网站。

http://www.oaktreecapital.com/

http://www.oaktreecapital.com/

.

。

Media Contacts

媒体联系人

Saol Therapeutics

Saol 治疗公司

Anna Stallmann

安娜·施塔尔曼

[email protected]

[email protected]

Oaktree

橡树

[email protected]

[email protected]

SOURCE Saol Therapeutics

来源：Saol Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示